Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical company focused on developing and commercializing innovative medications for pain management. The company aims to provide effective solutions for patients while ensuring responsible use of medications. In the competitive pharmaceutical industry, Collegium competes with companies like Amphastar Pharmaceuticals, Syndax Pharmaceuticals, Enanta Pharmaceuticals, and Ironwood Pharmaceuticals.
Collegium's Return on Invested Capital (ROIC) is 10.34%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 5.18%. This results in a ROIC to WACC ratio of 1.99, indicating that the company is efficiently utilizing its capital to generate returns above its cost. This is a positive indicator for investors, as it suggests that Collegium is effectively managing its resources.
In comparison, Amphastar Pharmaceuticals has a ROIC of 7.52% and a WACC of 7.55%, resulting in a ROIC to WACC ratio of 0.99. This suggests that Amphastar is not generating returns above its cost of capital, which may be a concern for investors looking for efficient capital utilization.
Syndax Pharmaceuticals and Enanta Pharmaceuticals both exhibit negative ROICs of -66.67% and -22.45%, respectively. With WACCs of 5.33% and 6.39%, their ROIC to WACC ratios are -12.515 and -3.512. These figures indicate inefficiencies in capital utilization, as both companies are operating at a loss and not generating returns above their cost of capital.
Ironwood Pharmaceuticals, on the other hand, demonstrates exceptional efficiency with a ROIC of 62.21% and a WACC of 6.21%. This results in a ROIC to WACC ratio of 10.01, highlighting Ironwood's ability to generate substantial returns above its cost of capital. This makes Ironwood the most efficient among the peers analyzed, with Collegium also showing strong performance in capital management.
